CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a po-...
Phase 1
Nashville, Tennessee, United States and 13 other locations
to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracyc...
Phase 3
Nashville, Tennessee, United States and 66 other locations
and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma...
Phase 1, Phase 2
Nashville, Tennessee, United States and 73 other locations
at different dosages in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM). Cem...
Phase 1, Phase 2
Nashville, Tennessee, United States and 12 other locations
CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non...
Phase 1
Nashville, Tennessee, United States and 34 other locations
A Phase 1/2 Study of bbT369, a dual targeting CAR T cell drug product with a gene edit, in Relapsed and/or Refractory B cell Non-Hodgkin...
Phase 1, Phase 2
Nashville, Tennessee, United States and 3 other locations
This study will enroll approximately 160 adult participants who have relapsed or refractory (r/r) iNHL to be infused with the study treatment, axicab...
Phase 2
Nashville, Tennessee, United States and 18 other locations
of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\^6 cells (flat dosing)....
Phase 1
Nashville, Tennessee, United States and 6 other locations
This is a phase 1 study to evaluate safety and dose-limiting toxicity of autologous CD30.CAR-T in subjects with relapsed or refractory CD30+ Non...
Phase 1
Nashville, Tennessee, United States and 3 other locations
lymphoblastic leukemia (ALL) or relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (NHL).As of October 2022, no furt...
Phase 1, Phase 2
Nashville, Tennessee, United States and 29 other locations
Clinical trials
Research sites
Resources
Legal